NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
OHSU Knight Cancer Institute
Seoul National University Hospital
Bristol-Myers Squibb
Eli Lilly and Company
University of Chicago
St. Joseph's Healthcare Hamilton
Dana-Farber Cancer Institute
University of California, San Francisco